Scienture (NASDAQ:SCNX) Research Coverage Started at Maxim Group

Maxim Group began coverage on shares of Scienture (NASDAQ:SCNX) in a report published on Tuesday, MarketBeat reports. The firm issued a buy rating and a $1.50 price objective on the stock.

A number of other equities analysts have also commented on SCNX. Wall Street Zen lowered shares of Scienture from a “hold” rating to a “sell” rating in a research report on Sunday, January 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Scienture in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $1.50.

Scienture Price Performance

SCNX stock opened at $0.45 on Tuesday. The stock has a market capitalization of $18.10 million, a price-to-earnings ratio of -0.45 and a beta of 3.02. The business’s fifty day moving average price is $0.49 and its two-hundred day moving average price is $0.73. Scienture has a fifty-two week low of $0.37 and a fifty-two week high of $3.61.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Scienture stock. Virtu Financial LLC acquired a new stake in shares of Scienture Holdings, Inc. (NASDAQ:SCNX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 89,930 shares of the company’s stock, valued at approximately $46,000. Virtu Financial LLC owned approximately 0.22% of Scienture at the end of the most recent reporting period. 5.68% of the stock is owned by institutional investors.

About Scienture

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.